TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01167738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1250 mg/mq days 1-28 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250 mg/mq days 1-28 every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 30 mg/mq on days 1 and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30 mg/mq on days 1 and 15 every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: 30 mg/mq on days 1 and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 30 mg/mq on days 1 and 15 every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: 800 mg/mq on days 1 and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 800 mg/mq on days 1 and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 2 g days 1-28 every 4 weeks
Study: NCT01298869

Intervention type: BIOLOGICAL
Intervention: HPV-6/11/16/18 vaccine
Description: HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
Study: NCT04644926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
Study: NCT03933618

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole 1mg

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 25mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo - Cap
Study: NCT02952092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Intravenous
Study: NCT02415699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Study: NCT02028559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propulse 1
Description: Move kidney stones with Propulse 1 device.
Study: NCT01896284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg aflibercept
Description: 0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
Study: NCT03042962

Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies
Study: NCT01673763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent insertion into the main pancreatic duct
Description: Stent insertion into the main pancreatic duct
Study: NCT02565719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Mg
Description: REP 2139-Mg = magnesium chelate complex of REP 2139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REP 2139-Mg
Description: REP 2139-Mg = magnesium chelate complex of REP 2139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread
Description: HBV RT polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread
Description: HBV RT polymerase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: HBV RT polymerase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: HBV RT polymerase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2165-Mg
Description: REP 2165-Mg = magnesium chelate complex of REP 2165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REP 2165-Mg
Description: REP 2165-Mg = magnesium chelate complex of REP 2165
Study: NCT03337932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 milligram Oral Tablet bid, 7 days
Description: Patients will receive doxycycline for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 milligram Oral Tablet bid, 14 days
Description: Patients will receive doxycycline for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Controls without a history of lyme disease.
Description: No intervention.
Study: NCT02788630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep hygiene counseling
Description: The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
Study: NCT02621346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery
Description: Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Maintenance
Description: Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bicep Curls
Description: Control group participants will complete a bicep exercise at a maintenance training intensity.
Study: NCT04085302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Behaviour Change Intervention
Description: 14 days
Study: NCT00382824

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: active drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01691521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab IV
Description: Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab SC
Description: Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Placebo
Description: Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Placebo
Description: Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo
Description: Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
Study: NCT01402843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pitavastatin, valsartan, placebo
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin, valsartan, placebo
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pitavastatin, valsartan, placebo
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pitavastatin, valsartan, placebo
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
Study: NCT03380078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teams Leadership Institute (TLI)
Description: TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
Study: NCT00916461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + treatment as usual.
Study: NCT00067119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01241383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
Study: NCT02712125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosorbide mononitrate
Description: 20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo vaginal tablets once daily until delivery
Study: NCT00357721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, 200 mg, twice daily, 7 days.
Study: NCT00357721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, 300 mg, twice daily, 8 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir Sulphate
Description: Capsules, Oral, 400 mg, twice daily, 9 days.
Study: NCT04146246

Intervention type: DIAGNOSTIC_TEST
Intervention: G6PD assay
Description: A test for G6PD deficiency.

Intervention type: DIAGNOSTIC_TEST
Intervention: G6PD assay
Description: A test for G6PD deficiency.
Study: NCT02085681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-medicine
Description: Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional referral
Description: All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
Study: NCT00270361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual long term cardiac medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Study: NCT02276924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser confocal microscopy
Description: Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
Study: NCT02087436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc Complete Microplasty
Description: Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc Complete Standard
Description: Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
Study: NCT03615781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two week's arm - surgery
Description: The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four week's arm - surgery
Description: The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two week's arm - drugs
Description: After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Four week's arm - drugs
Description: After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
Study: NCT00339690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MITE-T-FASTtest kit
Description: The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
Study: NCT06684912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: The number of bouts of exercise-recovery for each participant was tailored to achieve the desired EE. For example, a participant with a peak oxygen uptake (V̇O2) peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate continuous exercise
Description: Energy expenditure of exercise conditions (HIIE and MICE) were matched for energy expenditure. A participant with a V̇O2 peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
Study: NCT00294099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Aluminum hydroxide adjuvant.
Study: NCT04194320

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound (US) guided supraclavicular brachial plexus block
Description: Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound (US) guided supraclavicular brachial plexus block
Description: Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound (US) guided supraclavicular brachial plexus block
Description: Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
Study: NCT01059032

Intervention type: OTHER
Group type: OTHER
Intervention: Using a 3 dimentional post processing filter
Description: Using a 3 dimentional post processing filter
Study: NCT04071223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04531371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: post surgical agitation prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: post surgical agitation prophylaxis
Study: NCT02419482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4x4 minutes high intensity interval training
Description: Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10x1 minute high intensity interval training
Description: Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Study: NCT00672971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4% dimethicone foam
Description: The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1% permethrin
Description: Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
Study: NCT04266691

Intervention type: OTHER
Intervention: nonIntervention
Description: nonIntervention

Intervention type: OTHER
Intervention: nonIntervention
Description: nonIntervention
Study: NCT02935959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized ketamine
Description: Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized midazolam
Study: NCT01339910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Busulfan
Description: (Flu/Bu)~* Fludarabine: 30 mg/m\^2/day on Days -6 to -2 (total dose of 150 mg/m\^2)~* Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Melphalan
Description: (Flu/Mel)~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2 (total dose of 120 mg/m\^2)~* Melphalan: 140 mg/m\^2 on Day -2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan and Fludarabine
Description: (Bu/Flu)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m\^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -5 to -2~* Fludarabine: 30 mg/m\^2/day on Days -5 to -2: Flu (total dose of 120 mg/m\^2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan and Cyclophosphamide
Description: (Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide and Total Body Irradiation
Description: (Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)